The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 22, 2011
Filed:
Dec. 09, 2005
Jeannie M. Arruda, San Diego, CA (US);
Brian T. Campbell, San Diego, CA (US);
Nicholas D. P. Cosford, San Diego, CA (US);
Jacob M. Hoffman, Lansdale, PA (US);
Essa H. HU, Camarillo, CA (US);
Mark E. Layton, Harleysville, PA (US);
Yiwei LI, Ambler, PA (US);
Jun Liang, Palo Alto, CA (US);
Kevin J. Rodzinak, Schwenksville, PA (US);
Tony Siu, Brookline, MA (US);
Brian A. Stearns, San Diego, CA (US);
Lida R. Tehrani, San Diego, CA (US);
Mark T. Bilodeau, Lansdale, PA (US);
Peter J. Manley, Harleysville, PA (US);
Jeannie M. Arruda, San Diego, CA (US);
Brian T. Campbell, San Diego, CA (US);
Nicholas D. P. Cosford, San Diego, CA (US);
Jacob M. Hoffman, Lansdale, PA (US);
Essa H. Hu, Camarillo, CA (US);
Mark E. Layton, Harleysville, PA (US);
Yiwei Li, Ambler, PA (US);
Jun Liang, Palo Alto, CA (US);
Kevin J. Rodzinak, Schwenksville, PA (US);
Tony Siu, Brookline, MA (US);
Brian A. Stearns, San Diego, CA (US);
Lida R. Tehrani, San Diego, CA (US);
Mark T. Bilodeau, Lansdale, PA (US);
Peter J. Manley, Harleysville, PA (US);
Merck Sharp & Dohme Corp., Rahway, NJ (US);
Abstract
The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention. These substituted naphthyridines have unexpected advantageous properties when compared to other naphthyridines reported in PCT publication WO2003/086394, such unexpected advantageous properties may include increased cellular potency/solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity and so on.